Reduced cerebral expression of metabotropic glutamate receptor subtype 5 in men with fragile X syndrome.

Table S1. Concomitant medications of participants with fragile X syndrome from the Institute for Neurodegenerative Disorders. Table S2. Demographic and clinical characteristics of participants from the Institute for Neurodegenerative Disorders (IND). All participant are non-Hispanic. Table S3. Demographic and clinical data of participants from Johns Hopkins University (JHU). Table S4. Genetic and psychological assessments of participants from the Institute for Neurodegenerative Disorders. Table S5. Genetic and psychological assessments of participants with fragile X syndrome and family members from Johns Hopkins University. Table S6. Positron emission tomography (PET) data and analyses for participants from the Institute for Neurodegenerative Disorders. Table S7. Positron Emission Tomography (PET) data and analysis of participants from Johns Hopkins University. The authors thank Flora Tassone, Ph.D., Department of Biochemistry and Molecular Medicine, School of Medicine, UC Davis Health, Sacramento, California, for providing genetic and protein data about participants.补充表S1：来自神经退行性疾病研究所的脆性X综合征（Fragile X Syndrome）受试者伴随用药情况。补充表S2：来自神经退行性疾病研究所（Institute for Neurodegenerative Disorders, IND）的受试者人口统计学与临床特征数据，所有受试者均为非西班牙裔族群。补充表S3：来自约翰斯·霍普金斯大学（Johns Hopkins University, JHU）的受试者人口统计学与临床资料。补充表S4：来自神经退行性疾病研究所的受试者遗传学与心理学评估数据。补充表S5：来自约翰斯·霍普金斯大学的脆性X综合征受试者及其家属的遗传学与心理学评估数据。补充表S6：来自神经退行性疾病研究所的受试者正电子发射断层扫描（Positron Emission Tomography, PET）数据及分析结果。补充表S7：来自约翰斯·霍普金斯大学的受试者正电子发射断层扫描（PET）数据及分析结果。本研究作者感谢美国加州萨克拉门托市加州大学戴维斯分校医学院生物化学与分子医学系的弗洛拉·塔森（Flora Tassone）博士，为受试者提供遗传学与蛋白质相关数据。